Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)

Abstract

Introduction: Leucine-rich repeat kinase 2 (LRRK2) is a large (2527 residues) complex multi-domain protein that has GTPase and kinase domains. Autosomal dominant missense mutations in LRRK2 have been found in individuals with Parkinson's disease (PD) and are considered responsible for 1% of all cases of PD. Among the mutations confirmed to contribute to PD pathogenicity, G2019S is the most common cause of PD and it increases the kinase activity of LRRK2 by around threefold. LRRK2 has received considerable attention as a therapeutic target for PD, and LRRK2 inhibitors may help prevent and/or treat the disease.

Areas covered: LRRK2 inhibitors are being investigated by various industrial and academic institutions. The present review covers patents literature on small-molecule LRRK2 inhibitors patented between 2011 and 2013.

Expert opinion: Currently, wild-type and mutant LRRK2 are being examined as therapeutic targets for PD. In testimony to the significance of these novel targets, over 20 patent applications related to LRRK2 have been filed in the last 3 years. Several distinct chemotypes have been reported to be LRRK2 inhibitors with very good potency. These compounds are being used to elucidate the physiological and pathophysiological functions of LRRK2, and some may even emerge as therapeutics for PD.

Keywords::

• blood–brain barrier
• G2019S mutation
• kinase inhibitors
• leucine-rich repeat kinase 2
• l-DOPA
• leucine-rich repeat kinase 2 inhibitors
• neurodegenerative disease
• Parkinson's disease
• wild-type leucine-rich repeat kinase 2

Acknowledgements

We sincerely thank the reviewers of this manuscript for their valuable suggestions and comments.

Notes

This box summarizes key points contained in the article.